4394-02-9

Upstream product

• 5957-90-4 4-(2-pyridinyl)anisole 
• 110-86-1 pyridine 
• 33696-00-3 4-bromo-1-methoxy-2-nitrobenzene 
• 197958-29-5 pyridin-2-ylboronic acid 
• 167959-18-4 4-(2-pyridyl)-2-nitroaniline 
• 104-94-9 4-methoxy-aniline 
• 186581-53-3 diazomethane 
• 159958-44-8 2-(4-hydroxy-3-nitrophenyl)pyridine 

Downstream Products

• 158461-76-8 {1-Methyl-2-[5-pyridin-2-yl-2-(2,2,2-trifluoro-ethoxy)-phenylcarbamoyl]-ethyl}-carbamic acid tert-butyl ester 
• 158461-72-4 [2-(2-Methoxy-5-pyridin-2-yl-phenylcarbamoyl)-1-methyl-ethyl]-carbamic acid tert-butyl ester 
• 158461-36-0 2-[3-Nitro-4-(2,2,2-trifluoro-ethoxy)-phenyl]-pyridine 
• 158461-50-8 5-Pyridin-2-yl-2-(2,2,2-trifluoro-ethoxy)-phenylamine 
• 159958-44-8 2-(4-hydroxy-3-nitrophenyl)pyridine 
• 104994-90-3 α-(3-amino-4-methoxyphenyl)pyridine 

Relevant academic research and scientific papers

ARYL AND HETEROARYL COMPOUNDS, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF GALACTOCEREBROSIDASE

The application is directed to compounds of formulae (IA) and (IB): (IA) and (IB), and their salts and solvates, wherein R1a, R2a, A1, A2, A3, A4, R1b, R2b, B1, B2, B3, and G are as set forth in the specification, as well as to methods for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of, e.g., lysosomal storage diseases, such as Krabbe's disease, and α-synucleinopathies, such as Parkinson's disease.

Meta-Selective CAr-H Nitration of Arenes through a Ru3(CO)12-Catalyzed Ortho-Metalation Strategy

The first example of transition metal-catalyzed meta-selective CAr-H nitration of arenes is described. With the use of Ru3(CO)12 as the catalyst and Cu(NO3)2·3H2O as the nitro source, a wide spectrum of arenes bearing diversified N-heterocycles or oximido as the directing groups were nitrated with meta-selectivity exclusively. Mechanism studies have demonstrated the formation of a new 18e-octahedral ruthenium species as a key ortho-CAr-H metalated intermediate, which may be responsible for the subsequent meta-selective electrophilic aromatic substitution (SEAr). Moreover, this approach provides a fast-track strategy for atom/step economical synthesis of many useful pharmaceutical molecules.

2, 4- DI (PHENYLAMINO) PYRIMIDINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS

Novel pyrimidine derivatives of formula (I), to processes for their production, their use as pharmaceuticals in the treatment of neoplastic diseases, inflammatory and immune system disorders and to pharmaceutical compositions comprising them.

Synthesis and antiarrhythmic activity of disubstituted phenylpyridine derivative

A series of disubstituted phenylpyridine derivatives was synthesized and their antiarrhythmic effects against chloroform-induced ventricular arrhythmias in mice were examined. Among them, 2- and 3-[2-(3- aminobutyramido)-4-(2,2,2-trifluoroethoxy)phenyl]pyridines (23h, 24h) and 3- [2-(3-aminobutyramido)-4-ethoxyphenyl]pyridine (24i) showed potent antiarrhythmic activity. They had approximately twice the potency of mexiletine (III). Compound 24i was selected from this series as a candidate for further development; it was found to have a class I B electrophysiological character and to show a slow kinetic rate-dependent block (RDB) of the sodium channel in cardiac muscle.

Cardiotonic Agents. 1. Synthesis and Structure-Activity Relationships in a New Class of 3-,4-, and 5-Pyridyl-2(1H)-quinolone Derivatives

A series of 3-,4-, and 5-pyridyl-2(1H)-quinolone derivatives with H or HO or CH3O substituents in the 8-position were prepared and tested for positive inotropic activity.Several derivatives, especially 29, 9b, and 27 with a pyridyl ring in the 5-position,